HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 6, 3799-3808, February 9, 2007

This Article Full Text Full Text (PDF) All Versions of this Article: 282/6/3799    most recent M610185200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yang, W. Articles by Zhu, D. Search for Related Content PubMed PubMed Citation Articles by Yang, W. Articles by Zhu, D. Social Bookmarking                      What's this?

Myostatin Induces Cyclin D1 Degradation to Cause Cell Cycle Arrest through a Phosphatidylinositol 3-Kinase/AKT/GSK-3 Pathway and Is Antagonized by Insulin-like Growth Factor 1^*

Wei Yang, Yong Zhang, Yanfeng Li, Zhenguo Wu, and Dahai Zhu^¶1

From the National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, 5 Dong Dan San Tiao, Beijing 100005, China, the ^¶Molecular and Cellular Developmental Biology Laboratory, Harbin Institute of Technology, Harbin 150001, China, and the Department of Biochemistry, Hong Kong University of Science and Technology, Clearwater Bay, Kowloon, Hong Kong 999077, China

Myostatin is a transforming growth factor superfamily member and is known as an inhibitor of skeletal muscle cell proliferation and differentiation. Exposure to myostatin induces G₁ phase cell cycle arrest. In this study, we demonstrated that myostatin down-regulates Cdk4 activity via promotion of cyclin D1 degradation. Overexpression of cyclin D1 significantly blocked myostatin-induced proliferation inhibition. We further showed that phosphorylation at threonine 286 by GSK-3 was required for myostatin-stimulated cyclin D1 nuclear export and degradation. This process is dependent upon the activin receptor IIB and the phosphatidylinositol 3-kinase/Akt pathway but not Smad3. Insulin-like growth factor 1 (IGF-1) treatment or Akt activation attenuated the myostatin-stimulated cyclin D1 degradation as well as the associated cell proliferation repression. In contrast, attenuation of IGF-1 signaling caused C2C12 cells to undergo apoptosis in response to myostatin treatment. The observation that IGF-1 treatment increases myostatin expression through a phosphatidylinositol 3-kinase pathway suggests a possible feedback regulation between IGF-1 and myostatin. These findings uncover a novel role for myostatin in the regulation of cell growth and cell death in concert with IGF-1.

Received for publication, October 31, 2006 , and in revised form, November 24, 2006.

^* This work was supported by National Basic Research Program of China Grants 2005CB522400 and 2005CB522507 and National Natural Science Foundation of China Grants 30025027, 30400231, 30570984, 30429002, and 30330430. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, 5 Dong Dan San Tiao, Beijing 100005, China. Tel.: 86-10-65296949; Fax: 86-10-65105083; E-mail: dhzhu{at}pumc.edu.cn.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. U. Trendelenburg, A. Meyer, D. Rohner, J. Boyle, S. Hatakeyama, and D. J. Glass Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size Am J Physiol Cell Physiol, June 1, 2009; 296(6): C1258 - C1270. [Abstract] [Full Text] [PDF]

				S. P. Narayanan, A. I. Flores, F. Wang, and W. B. Macklin Akt Signals through the Mammalian Target of Rapamycin Pathway to Regulate CNS Myelination J. Neurosci., May 27, 2009; 29(21): 6860 - 6870. [Abstract] [Full Text] [PDF]

				T. A. Souza, X. Chen, Y. Guo, P. Sava, J. Zhang, J. J. Hill, P. J. Yaworsky, and Y. Qiu Proteomic Identification and Functional Validation of Activins and Bone Morphogenetic Protein 11 as Candidate Novel Muscle Mass Regulators Mol. Endocrinol., December 1, 2008; 22(12): 2689 - 2702. [Abstract] [Full Text] [PDF]

				B. D. Rodgers and D. K. Garikipati Clinical, Agricultural, and Evolutionary Biology of Myostatin: A Comparative Review Endocr. Rev., August 1, 2008; 29(5): 513 - 534. [Abstract] [Full Text] [PDF]

				Z. B. Li, H. D. Kollias, and K. R. Wagner Myostatin Directly Regulates Skeletal Muscle Fibrosis J. Biol. Chem., July 11, 2008; 283(28): 19371 - 19378. [Abstract] [Full Text] [PDF]

				B.-W. Wang, H. Chang, P. Kuan, and K.-G. Shyu Angiotensin II activates myostatin expression in cultured rat neonatal cardiomyocytes via p38 MAP kinase and myocyte enhance factor 2 pathway J. Endocrinol., April 1, 2008; 197(1): 85 - 93. [Abstract] [Full Text] [PDF]

				C. L. Mendias, K. I. Bakhurin, and J. A. Faulkner Tendons of myostatin-deficient mice are small, brittle, and hypocellular PNAS, January 8, 2008; 105(1): 388 - 393. [Abstract] [Full Text] [PDF]

				Y.-W. Chen, C. M. Gregory, M. T. Scarborough, R. Shi, G. A. Walter, and K. Vandenborne Transcriptional pathways associated with skeletal muscle disuse atrophy in humans Physiol Genomics, November 14, 2007; 31(3): 510 - 520. [Abstract] [Full Text] [PDF]

				J.-s. Kim, J. K. Petrella, J. M. Cross, and M. M. Bamman Load-mediated downregulation of myostatin mRNA is not sufficient to promote myofiber hypertrophy in humans: a cluster analysis J Appl Physiol, November 1, 2007; 103(5): 1488 - 1495. [Abstract] [Full Text] [PDF]